CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Surprisingl...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Amlan, Haque, Inamul, Ray, Priyanka, Ghosh, Arnab, Dutta, Debasmita, Quadir, Mohiuddin, De, Archana, Gunewardena, Sumedha, Chatterjee, Indranil, Banerjee, Snigdha, Weir, Scott, Banerjee, Sushanta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981588/
https://www.ncbi.nlm.nih.gov/pubmed/33745223
http://dx.doi.org/10.1002/prp2.753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981588/
https://www.ncbi.nlm.nih.gov/pubmed/33745223
http://dx.doi.org/10.1002/prp2.753

Ejemplares similares